Primary Biliary Cholangitis Therapeutics Market to Reach $1.36 Billion by 2032, Growing at 7.1% CAGR
The global primary biliary cholangitis therapeutics market size was valued at US$732.5 million in 2023 and is projected to reach US$1358.1 billion by 2032, growing at a CAGR of 7.1% from 2024 to 2032.
Ctexli’s approval further entrenches Mirum as a leader in rare liver diseases, alongside its cornerstone product Livmarli and ...
The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...
Mirum Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved CTEXLItm (chenodiol) tablets, a bile acid, for the treatment of adults with cerebrotendinous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results